These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Lack of association of HLA-DR antigens with progressive systemic sclerosis (scleroderma). Niks M; Rovenský J; Nyulassy S; Buc M; Stefanovic J; Zitnan D Tissue Antigens; 1982 Mar; 19(3):238-9. PubMed ID: 6953619 [No Abstract] [Full Text] [Related]
23. [Anti-Scl-70 and anti-centromere autoantibodies. Biological markers of 2 forms of systemic scleroderma]. Johanet C; Agostini MM; Vayssairat M; Abuaf N Presse Med; 1989 Feb; 18(5):207-11. PubMed ID: 2522207 [TBL] [Abstract][Full Text] [Related]
24. Association of DM genes in systemic sclerosis is secondary to the association with HLA genes. Takeuchi F; Takizawa K; Nabeta H; Kuwata S; Ito K Scand J Rheumatol; 1997; 26(3):174-9. PubMed ID: 9225871 [TBL] [Abstract][Full Text] [Related]
25. Genetic factors in scleroderma. Briggs D; Black C; Welsh K Rheum Dis Clin North Am; 1990 Feb; 16(1):31-51. PubMed ID: 2406810 [TBL] [Abstract][Full Text] [Related]
26. Intradermal Injections of Bleomycin to Model Skin Fibrosis. Yamamoto T Methods Mol Biol; 2017; 1627():43-47. PubMed ID: 28836193 [TBL] [Abstract][Full Text] [Related]
27. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Mayes MD Environ Health Perspect; 1999 Oct; 107 Suppl 5(Suppl 5):743-8. PubMed ID: 10502540 [TBL] [Abstract][Full Text] [Related]
28. The immunogenetic background of scleroderma--an overview. Black C; Briggs D; Welsh K Clin Exp Dermatol; 1992 Mar; 17(2):73-8. PubMed ID: 1516246 [TBL] [Abstract][Full Text] [Related]
29. [Genetics in systemic sclerosis]. Skretkowicz J; Skretkowicz-Szarmach K Pol Merkur Lekarski; 2006 Jan; 20(115):117-20. PubMed ID: 16617751 [TBL] [Abstract][Full Text] [Related]
30. Fc gamma RII restriction fragment length polymorphism (RFLP): analysis in systemic lupus erythematosus and scleroderma and evidence of an alpha gene duplication. Jazwinska EC; Olive C; Hogarth PM; Gatenby PA; Serjeantson SW Clin Exp Immunol; 1991 Jan; 83(1):47-51. PubMed ID: 1671005 [TBL] [Abstract][Full Text] [Related]
33. Recent advances in animal models of systemic sclerosis. Asano Y J Dermatol; 2016 Jan; 43(1):19-28. PubMed ID: 26782003 [TBL] [Abstract][Full Text] [Related]
34. Genetics of scleroderma. Black CM; Welsh KI Clin Dermatol; 1994; 12(3):337-47. PubMed ID: 7954192 [No Abstract] [Full Text] [Related]
35. Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma. Tsujino K; Sheppard D Curr Rheumatol Rep; 2016 Jan; 18(1):4. PubMed ID: 26711695 [TBL] [Abstract][Full Text] [Related]
37. Increased expression of intercellular adhesion molecule 1 on the fibroblasts of scleroderma patients. Needleman BW Arthritis Rheum; 1990 Dec; 33(12):1847-51. PubMed ID: 1979737 [TBL] [Abstract][Full Text] [Related]
38. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Yamamoto T Arch Dermatol Res; 2006 Feb; 297(8):333-44. PubMed ID: 16402183 [TBL] [Abstract][Full Text] [Related]
39. Lack of an association between diffuse systemic sclerosis and HLA-DR1 or HLA-DR5. Kratz LE; Boughman JA; Needleman BW Dis Markers; 1989; 7(4):209-13. PubMed ID: 2573446 [TBL] [Abstract][Full Text] [Related]